MUHAS Newsletter: HIV vaccines in PrEPVacc trial fail to reduce infections: Results announced at AIDS 2024 conference
PrEPVacc Vaccine Trial Results Dissemination to participants in Masaka, Uganda
PrEPVacc meets the media in Masaka
PrEPVacc Vaccine Results Dissemination at SAMRC Verulam: A Step Towards Hope
FAQs for PrEPVacc's vaccine result
Media coverage of PrEPVacc's July 2024 vaccine result announcement
Eddagala ly’okugema eryagezeseddwa mu kunoonyereza kwa PrEPVacc teryasobodde kuziyiza kawuka ka Siriimu
Taarifa kwa Umma: Chanjo za VVU zilizojaribiwa katika utafiti wa PrEPVacc zashindwa kupunguza maambukizi
News Release: HIV vaccines tested in PrEPVacc fail to reduce infections
AIDS 2024: “I am not sick, why should I swallow daily pills?”: non-uptake of, and adherence to daily oral pre-exposure prophylaxis among adults at high-risk of HIV in Masaka, Uganda
AIDS 2024: Knowledge and experiences of participating in an HIV vaccine efficacy trial with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda
AIDS 2024: HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial: a qualitative longitudinal study, South Africa
AIDS 2024: Disclosing of Participation in an HIV Vaccine Trial in Southwestern Uganda – the effect on participant engagement
AVAC briefing on PrEPVacc: An in-depth look at the trial, and what’s next
Media coverage of PrEPVacc's December 2023 study update
News Release: Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports
STAT: 'Can the world still invent an HIV vaccine? Progress in one area creates new problem'
CNN reports on ‘the last roll of the dice’ for an HIV vaccine this decade
News Release: African-led PrEPVacc HIV prevention study completes its enrolment
Video to help inform PrEPVacc participants posted online
